论文部分内容阅读
To the editor:We read with great interest the article by Lin and co-authors.1 The authors assessed the clinical usefulness of plasma tissue inhibitor ofmetalloproteinase 1 (TIMP-1) as a potential blood biomarker for glioma.They concluded that plasma TIMP-1 is associated with the diagnosis and prognosis of glioma patients and have better usefulness for guiding clinical decision making than plasma matrix metalloproteinase-9 (MMP-9).Although we commend the authors for the excellent data that they have provided,some comments may be of beneficial.